外用红色诺卡氏菌细胞壁骨架治疗宫颈持续高危型HPV感染的临床效果

Clinical effect of topical Nocardia rubra cell wall skeleton in the treatment of persistent high-risk HPV infection of the cervix

目的探讨外用红色诺卡氏菌细胞壁骨架(Nr-CWS)治疗宫颈持续高危型人乳头瘤病毒(HPV)感染的临床效果。方法选取徐州医科大学附属医院2018年6月—2020年1月收治的宫颈持续高危型HPV感染者273例,采用随机数字表法分为观察组(n=136)和对照组(n=137)。观察组采用Nr-CWS治疗,对照组予以重组人干扰素α-2b凝胶治疗。比较两组治疗后3、6个月临床疗效及治疗过程中不良反应发生情况。结果观察组治疗后3个月及6个月的总有效率均显著高于对照组,差异有统计学意义(P<0.05)。单个亚型感染亚组与多个亚型感染亚组总有效率比较,差异无统计学意义(P>0.05)。HPV-16型亚组、HPV-16合并其他多个亚组、HPV-18合并其他多个亚组、HPV-18合并HPV-16型亚组、HPV-18合并HPV-16合并其他多个亚组、单个其他高危亚型亚组及多个其他高危亚型亚组的总有效率均高于HPV-18型亚组,差异有统计学意义(P<0.05)。HPV-16型亚组、HPV-16合并其他多个亚组、HPV-18合并其他多个亚组、HPV-18合并HPV-16型亚组及HPV-18合并HPV-16合并其他多个亚组的总有效率均高于单个其他高危亚型亚组、多个其他高危亚型亚组,差异有统计学意义(P<0.05)。两组治疗过程中不良反应发生率比较,差异无统计学意义(P>0.05)。结论外用Nr-CWS治疗宫颈高危型HPV感染的效果优于重组人干扰素α-2b凝胶,值得临床推广。

Objective To explore clinical effect of topical Nocardia rubra cell wall skeletal(Nr-CWS)in the treatment of cervical high-risk human papillomavirus(HPV)infection.Methods All of 273 cervical high-risk HPV patients admitted to Affiliated Hospital of Xuzhou Medical University from June 2018 to January 2020 were collected,they were divided into observation group(n=136)and control group(n=137).Observation group was treated with Nr-CWS,while control group was treated with recombinant human interferonα-2b gel.Clinical efficacy after treatment of three months and six months and adverse reactions during treatment were compared between two groups.Results Total effective rate of observation group after treatment of three months and six months was significantly higher than that of control group(P<0.05).There was no significant difference in total effective rate between single subtype infection subgroup and multiple subtype infection subgroup(P>0.05).Total effective rate of HPV-16 subgroup,HPV-16 with other subgroups,HPV-18 with other subgroups,HPV-18 with HPV-16 subgroups,HPV-18 with HPV-16 subgroups,single other high-risk subtype subgroups and multiple other high-risk subtype subgroups were higher than those of HPV-18 subgroup(P<0.05).Total effective rates of HPV-16 subgroup,HPV-16 with other subgroups,HPV-18 with other subgroups,HPV-18 with HPV-16 subgroups and HPV-18 with HPV-16 and other subgroups were higher than those of single other high-risk subtype subgroups and multiple other high-risk subgroups(P<0.05).There was no significant difference in the incidence rate of adverse reaction between two groups during treatment(P>0.05).Conclusion The efficacy of topical Nr-CWS in the treatment of cervical high-risk HPV infection is better than that of recombinant human interferonα-2b gel,which is worthy of clinical promotion.